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Caspase-8 is a key initiator of death receptor-induced apoptosis. Here we report a novel short isoform of caspase-8 (caspase-8s),
which encodes the ﬁrst (Death Eﬀector Domain) DED and part of the second DED, missing the C-terminal caspase domain. In
vivobindingassaysshowedthattransfectedcaspase-8sboundto(Fas-associateddeathdomainprotein)FADD,theadaptorprotein
in (death-induced signal complex) DISC. To investigate the potential eﬀects of caspase-8s on cell apoptosis, Jurkat cells were stably
transfected with caspase-8s. Overexpression of caspase-8s increased sensitivity to the apoptotic stimuli, Fas-agonistic antibody
CH11. These results suggest that caspase-8s may act as a promoter of apoptosis through binding to FADD and is involved in the
regulation of apoptosis. In addition, the results also indicate that the ﬁrst DED was an important structure mediating combination
between caspase-8 and FADD.
Copyright © 2009 Zhifang Xu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Apoptosis, or programmed cell death, is orchestrated by
a family of proteases known as caspases that cleave their
substrates after speciﬁc aspartic acid residues [1]. Caspases,
including initiator caspases and eﬀector caspases, are synthe-
sized as catalytically inactive precursor proteins that become
activated in response to speciﬁc death stimuli. The activation
of initiator caspases such as caspase-8, -10, and -9 usually
requires the assembly of the multicomponent complex DISC
or apoptosome [2] .T h ep r o c e s s e sh a v eb e e nd e s c r i b e da s
two major pathways: extrinsic and intrinsic pathway. In the
extrinsic pathway, apoptosis is mediated primarily by tumor
necrosis factor (TNF) 1 family death receptors (DRs) such as
CD95 or TRAIL receptors. Upon activation of the DR, the
adaptor molecule FADD/Mort-1 is recruited to the receptors
through its C-terminal death domain motif while it binds
through its N-terminal DED to the two DED repeats in
the N-terminal of caspase-8, forming DISC [3–5], and the
resultant DISC will trigger the activation of procaspase-8.
The functional caspase-8 protease is then released into the
cytosol, where it cleaves a number of cellular substrates such
as eﬀector caspases (caspase-3, -6, -7) initiating a caspase
cascade and the subsequent apoptotic events. The active
caspase-8 also mediates the proteolytic cleavage of Bid into
tBid,whichistranslocatedtomitochondriaandampliﬁesthe
intrinsicapoptosispathway.Therefore,caspase-8playsavital
role in the propagation of enzymatic cascade that results in
cell apoptosis [6–9].
To date, eight diﬀerent isoforms, including Mcha1-3,
Mchb1–4, and Mch5 (also designated as caspase-8/a–h) have
been described at the mRNA level [10]. In this study, we
found a new caspase-8 isoform in acute leukemia (AL) and
normal BMMNCs (bone marrow mononuclear cells), which
encodes the ﬁrst DED and part of the second DED, missing
the C-terminal catalysis domain. Functional analysis indi-
catedthatthenewisoformcouldbindtoFADDandpromote
the apoptosis stimulated by Fas-agonistic antibody CH11
when stable transfected in Jurkat cells. In the caspase-8-
induced apoptosis pathway, the interaction between caspase-
8 and FADD is necessary for the formation of the DISC. But
there is a controversy about the functions of the two DEDs2 Journal of Biomedicine and Biotechnology
of caspase-8 in the interaction between caspase-8 and FADD.
The novel caspase-8s isoform we obtained only carries the
ﬁrst DED and a small part of the second DED, but it still
can interact with FADD, indicating that the ﬁrst but not
the second DED represents a crucial element in interaction
between caspase-8 and FADD, and that the second DED is
not a necessary domain for caspase-8 to bind to FADD.
2.MaterialsandMethods
2.1. Acute Leukemia and Normal Samples. Bone marrow
samples were obtained from patients with AL enrolled in the
InstituteofHematologyandBloodDiseaseHospital,Chinese
Academy of Medical Sciences. As control, bone marrow
samples were obtained from healthy donors for hematopoi-
etic stem cell transplantation as well. All samples were
collected under informed consent of the subjects. BMMNCs
were prepared by density gradient centrifugation over Ficoll
solution (Invitrogen, USA) following the instructions of the
manufacturer.
2.2. Cell Culture and Reagents. Human embryonic kid-
ney 293T cells were cultured in Dulbecco modiﬁed Eagle
medium (Life Technologies, USA). Human T-cell leukemia
Jurkat cells were cultured in 1640 medium supplemented
with 10% fetal calf serum at 37◦C in a humidiﬁed environ-
ment of 5% CO2. Anti-Fas (human, activating), clone CH11
(Upstate, CA), was used as apoptosis inducer.
2.3. RT-PCR Assays. Total RNA was extracted from 1 ×
106 cells using Trizol (Invitrogen, USA) according to man-
ufacturer’s protocol. RNA concentration was determined
by spectrophotometry at 260nm/280nm. OD260/OD280
= 1.8–2.0 was taken as the range of pure RNA. cDNA
was synthesized from 2μg RNA with Moloney murine
leukemiavirusreversetranscriptase(MMLV,Promega,USA)
following the procedure provided by the manufacturer. PCR
was performed to investigate the expression of caspase-
8 mRNA with the primers: sense primer 5 -AATGTT-
GGAGGAAAGCAATC-3  and antisense primer 5 -CAT-
AGTCGTTGATTATCTTCAGC-3 . PCR was carried out
using Taq polymerase (Takara, Japan) and conducted as
follows: 95◦C 5minutes, 35 cycles of 95◦C 30seconds, 55◦C
30seconds, 72◦C4 5s e c ,a n d7 2 ◦C 8minutes. Primers span-
ning the whole CDS of caspase-8 transcript are: sense primer
5 -CGGGATCCGCCATGGACTTCAGCAGAAATC-3  and
antisense primer 5 -TCCCCCGGGCACCATCAATCAGAA-
GGG-3 .P C Rw a sc o n d u c t e da sf o l l o w s :9 5 ◦C5m i n u t e s ,3 5
cyclesof95◦C30seconds,55◦C1minute,72 ◦C1minute,and
72◦C 8minutes. The whole CDS region of FADD (GenBank
accession no.NM 003824) was ampliﬁed with the sense
primer 5 -GAATTCGACCCGTTCCTGGTGCT-3  andanti-
sense primer 5 -CTCGAGAGTGCTGGGCTACCTTCC-3 
under the following conditions: 95◦C5 m i n u t e s ,3 5c y c l e s
of 95◦C 45seconds, 55◦C 45seconds, 72◦C 50seconds, and
72◦C 8minutes. The PCR products of the CDS of caspase-
8, caspase-8s and FADD were cloned into the pMD18-T
vector (Takara, Japan) and sequenced by ABI PRISM 377-
96geneticanalyzer(AppliedBiosystems,USA).Theresulting
plasmids were named pMD18-T-casp-8, pMD18-T-casp-8s
and pMD18-T-FADD, respectively.
2.4. Western Blot Assays. Cell pellets were lysed in lysis
buﬀer (50mM KCl, 2mM MgCl2,1 m ME D T A ,5 m M
DTT, 25mM Tris (PH 7.5), 1μg/mL leupeptin, 10μg/mL
aprotinin, and 1mM phenylmethylsulfonyl ﬂuoride) on ice
for 30minutes and centrifuged for 5min at 20,000g at
4◦C. Protein concentration of the supernatant was deter-
mined using BCA protein assay reagents (Pierce, USA). The
equal amounts of protein (50μg) were separated by 10%
sodium dodecylsulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), electroblotted on nitrocellulose membranes,
and immunostained with rabbit antiprocaspase-8 (C7849,
Sigma) followed by horseradish peroxidase-conjugated
antirabbit secondary antibodies (Jackson ImmunoResearch
Laboratoriesm Inc, USA). Finally, the proteins were detected
using enhanced chemiluminescence (Pierce, USA) according
to the manufacturer’s instructions.
2.5. In Vivo Protein Binding Assays. The pMD18-T-casp-
8 and pMD18-T-casp-8s were digested with restriction
enzymes BamH I and EcoR I; the products containing
only the two DEDs of caspase-8 and caspase-8s were then
cloned into the pcDNA 3.1 to construct the expression
vectors pcDNA3.1-casp-8-2DED and pcDNA3.1-casp-8s-
2DED. The pMD18-T-FADD was digested with EcoR I and
Xho I to construct pcDNA3.0-FADD. 293T cells were tran-
siently transfected using calcium phosphate precipitation
method and harvested after 48hours, and then the cells were
lysed and cleared by centrifugation. Rabbit anti-FADD (H-
181 sc-5559, Santa Cruz) was added to the supernatant, and
the cell lysate/antibody mixture was incubated overnight at
4◦C on a rotator, then protein A or G agarose bead was
added to the immunocomplex and incubated for another
1h on a rotator, the immunoprecipitate was collected
by centrifugation for 5 minutes at 20,000g at 4◦C, the
supernatant was discarded, and the beads were washed for
4 times with ice-cold PBS and resuspended in SDS-PAGE
sample buﬀer and mixed gently and boiled for 5 minutes.
Then western blot was performed with antiprocaspase-8 as
described above.
2.6. HIV-Based Lentivector Expression Vector Construction
and Stable Transfection. A fragment encoding caspase-8s
protein was ampliﬁed by PCR from pMD18-T-casp-8s vec-
tor.Thesequencesoftheprimersweredevisedasfollows:for-
ward 5 CCGGAATTCCGGATGGACTTCAGCAGAAAT-
C3 ,a n dr e v e r s e5  CGCGGATCCGCGATCTTCAGCAGG-
CTCTTG3 . The 414bp PCR product was inserted into
pCDH1-MCS1-EF1-copGFP(SBI,USA),whichwasanHIV-
based lentivector expression vector. A positive recombinant
was identiﬁed by utilizing EcoR I/BamH I double digestion
and direct sequencing. This construct and the other three
packing plasmid mixture pPACKH1-GAG, pPACKH1-REV
and, pVSV-G were transfected into 2.5 × 105 293T cells inJournal of Biomedicine and Biotechnology 3
six-wellplateusingcalciumphosphateprecipitationmethod.
Viral supernatant was harvested after 48hours and added
to the 2 × 105 Jurkat cells at diﬀerent dosages in 24-well
plates. At 6hours after infection, the culture medium was
changed and followed by incubation at 37◦C for 48hours.
As a control, a parallel vector without an insert was also
performed.Bothﬂuorescentmicroscopyandﬂowcytometric
analysis of GFP were used to monitor lentivector infection
of Jurkat cells. Individual clones with GFP expression were
isolated by limited dilution, and stable cell lines containing
pCDH1 empty vector and pCDH1-caspase-8s were estab-
lished. Caspase-8s expression was conﬁrmed by Western blot
analyses.
2.7. Assessment of Cell Apoptosis and Viability. Empty vector
or caspase-8s–transfected Jurkat cells and wild-type Jurkat
cells were untreated or treated with monoclonal antihuman
Fas antibody (clone CH11), and then the annexin V–
PE/7-AAD apoptosis detection kit (Pharmingen, San Diego,
CA) was used to determine the frequency of apoptosis
in cells according to the manufacturer’s instructions. The
cells were analyzed on the FACSscan. Early apoptotic cells
were deﬁned as those cells with Annexin V-PE+/7-AAD−
in the GFP expression positive cells. Apoptosis assays were
run in triplicate. DNA ladder formation was analyzed by
conventional electrophoresis. Approximately 2 × 106 cells
were collected and washed twice with PBS. The pellet was
incubated with lysis buﬀer (10mM Tris-HCl pH 8.0, 0.15M
Nacl, 10mM EDTA, 0.5% sodium lauroylsarcosinate (SDS),
10μM proteinase K, 100μM RNase A) at 50◦Cf o r2h o u r s .
DNA was extracted by phenol and ethanol precipitation.
After measuring the DNA concentration, an equal amount
of DNA was examined on a 2% agarose gel stained with
ethidium bromide (EB).
MTT assay was performed as previously described [11].
Brieﬂy, 2 × 105 c e l l sw e r ep l a t e di ne a c hw e l lo f9 6 - w e l l
microtiter plates with 100μL of fresh medium containing
CH11 in various concentrations. After 24h of further
incubation, 20μL of MTT solution (2.5mg/mL) was added
to each well and the cells were further incubated for 4h. The
mediumwasthenremovedandtheformedformazancrystals
were dissolved in 150μL of dimethyl sulfoxide (Sigma, USA).
The plates were placed on a plate shaker for 10min and
the absorbance of the resulting solution was immediately
measured at 546nm using a microplate reader (SLT-Lab,
Salzburg, Austria). Inhibition ratio was calculated with the
formula: inhibitory rate = (1 − T/C) × 100% where T is the
absorbance rate of treatment group with CH11 and C is the
absorbance rate of control group. These experiments were
repeated three times.
2.8. Assessment of Mitochondrial Membrane Potential.
Mitochondrial membrane potential was measured using
DiOC6/PI test. 5 × 105 cells were washed in PBS and
incubated at 37◦C for 30min with 40nM 3,3 dihexyloxa-
carbocyanine (DiOC6, Sigma aldrich) in combination with
5mg/mL propidium iodide (PI, Sigma). The ﬂuorescence
was measured by ﬂow cytometry.
2.9. Detection of Fas Expression by Semiquantitative RT-
PCR and Flow Cytometric Analysis. Total RNA was extracted
from wild-type Jurkat cells, empty vector, and caspase-
8s-transfected Jurkat cells; then RT-PCR was performed
with the sense primer 5 -CAAGGGATTGGAATTGAGGA-
3  and antisense primer 5 -GACAAAGCCACCCCAAGTTA-
3  under the following conditions: 94◦C 5min, 28 cycles
of 94◦C4 5 s e c ,5 8 ◦C5 0 s e c ,7 2 ◦C5 0 s e c ,a n d7 2 ◦C8 m i n
[12]. Each reverse-transcribed mRNA product was inter-
nally controlled by GADPH. Cell surface Fas antigen, were
quantiﬁed as follows: cells (5 × 105 cells/sample) were
collected and washed with PBS and then were incubated
with PE anti-human Fas (CD95) monoclonal Ab (DX-
2, Biolegend, San Diego, CA) or PE-conjugated mouse
IgG1 (Pharmingen) as a isotype negative control at room
temperature for 30 min. After two washes with PBS, the
cells were analyzed for surface Fas expression by ﬂow
cytometry.
3. Results and Discussion
3.1. Identiﬁcation of a Novel Isoform of Caspase-8 (Caspase-
8s). The human caspase-8 gene encodes an interleukin-1b
converting enzyme-(ICE-) related cysteine protease. It was
reported that the caspase-8 gene contains at least 11 exons
on human chromosome band 2q33–34, a region where loss
of heterogeneity (LOH) has been found in a number of
tumors [13]. In a panel of human cancer and cell lines,
mutations of caspase-8 gene have also been reported [14–
17]. Recent studies showed that the hypermethylation of
the caspase-8 gene promoter region and subsequent lack of
caspase-8 expression is related to some tumor cells [18–21].
All these researches suggested that abnormalities of caspase-
8 gene may be correlated with tumors. In our study, reverse
transcriptase-polymerase chain reaction (RT-PCR) was per-
formed to investigate the expression of caspase-8 mRNA
in BMMNCs derived from AL patients. To our surprise,
a shorter ampliﬁed product was visible in addition to the
wild type product of caspase-8 (Figure 1(a)). By sequencing,
a 106bp deletion was identiﬁed compared to the released
caspase-8 database (GenBank accession no.NM 033355).
Subsequently, the entire CDS (coding sequence region)
of this short caspase-8 transcript as well as the part of
untranslated region (UTR) was ampliﬁed and sequenced,
and no other mutations were found in addition to the 106bp
deletion. The new caspase-8 transcript was also expressed
in BMMNCs from healthy individuals and was named as
caspase-8s (caspase-8 short form, GenBank accession no.
EU670044).Wenextexaminedwhethercaspase-8stranscript
is also expressed in cell lines. RT-PCR detected transcripts
representingcaspase-8aswellascaspase-8sinmostcelllines.
RT-PCR also revealed that the ratio of caspase-8 to caspase-
8s varied in diﬀerent cell lines, but the expression level of
caspase-8 mRNA was higher than that of caspase-8s in all the
cell lines (Figure 1(b)).
Analyses of nucleotide and deduced amino acid
sequences revealed that the 106bp deletion resulted in a
frameshift mutation carrying a stop codon and termination
of the transcript in advance, with the predicted generation4 Journal of Biomedicine and Biotechnology
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Figure 1: (a) Identiﬁcation of a novel isoform of caspase-8 (caspase-8s): RT-PCR analysis of mRNA expression of caspase-8s from the bone
marrow cells of AL individual. The PCR products were separated on 1.5% agarose gel and visualized by ethidium bromide staining. In
addition to the expected bands (380bp) representing wild type caspase-8, a small amplicon representing caspase-8s was identiﬁed (274bp).
(b)Coexpressionofcaspase-8andcaspase-8sinvariouscelllines:RT-PCRwascarriedoutwithRNAisolatedfromvariouscelllinesasdescribed
under“Materials andMethods.”ThePCRproductswereresolvedon1.5%agarosegelandvisualized byethidiumbromidestaining.GAPDH
was used as a loading control. R = densitometrical units of caspase-8/densitometrical units of GAPDH.
of a 108aa protein, as compared with the 479aa of caspase-8
(GenBank accession no.AAD24962). The molecular mass
of the predicted protein was estimated to be 13KD. The
complementary DNA (cDNA) and protein sequences of
which were shown in Figure 2. By Western blot assays, we
detected the caspase-8s protein product existed in some
but not all leukemia samples. Some acute leukemia patient
examples of the Western blots are shown in Figure 3.
For caspase-8, eight diﬀerent isoforms, including
Mcha1–3, Mchb1–4, and Mch5, have been described at
the mRNA level [10]. Mcha1, Mcha2, and Mch5 are the
three procaspase-8 isoforms, all of which possess a long
N-terminal prodomain harboring two highly homologous
DEDs, DED1 (1–75aa) and DED2 (99–176aa), followed by
a C-terminal protease domain that can be divided into two
subunits, p18 and p11. mRNA of these three procaspase-8
isoforms are expressed in a wide variety of tissues, with the
highest expression in peripheral blood leukocytes, spleen,
thymus, and liver but barely detectable expression in brain,
testis, and skeletal muscle. But only two of them, Mcha1
and Mcha2, were detected at the protein level of all cell lines
tested. Both isoforms were recruited and activated by the
DISC with identical kinetics [22]. Other isoforms, Mcha3
that lacks DED, and Mchb1–4 that lacks catalytic domain,
are supposed to modulate the activity of caspase-8. Caspase-
8L is a recently reported novel isoform of caspase-8, which
was generated by alternative splicing of intron 8, carrying
a 136bp insertion and frame shift of the transcript. The
transcript misses the catalytic site of caspase-8 but retains
the DEDs. Functional assays indicated that caspase-8L acted
as an inhibitor of caspase-8 by interfering with the binding
of caspase-8 to FADD and was involved in the regulation
of Fas-mediated apoptosis [23]. Kisenge et al. [24] also
conﬁrmed the existence of a caspase-8 variant in some
neuroblastoma cell lines, which was impaired in the ﬁrst
DED and showed moderate sensitivity to Fas-mediated cell
death. In our study, the new caspase-8s isoform only carries
the ﬁrst DED (75aa) and part of the second DED (7aa),
which is not reported in the published literature.
3.2. Caspase-8s as well as Caspase-8 Binds to FADD. In
the caspase-8-induced apoptosis pathway, the interaction
between caspase-8 and FADD is necessary for the forma-
tion of the DISC. To determine whether caspase-8s can
bind to FADD through its incomplete DEDs and whether
“two” intact tandemly repeated DEDs are necessary for
interacting between caspase-8 and FADD, we performed in
vivo binding and co-immunoprecipitation assays; the results
demonstrated the speciﬁc binding of FADD to caspase-
8s as well as to caspase-8 (Figure 4). The apoptotic signal
from ligand-induced oligomerization of death receptors is
mediated by a complex of proteins containing specialized
interaction domains. This complex consists of the death
domain(DD),thecaspaserecruitmentdomain(CARD),and
the DED. The DED was ﬁrst described in the FADD/Mort1
protein and later shown to also occur in several otherJournal of Biomedicine and Biotechnology 5
241 atggtgccagg aaagggtgg agcggattat attctcctgc cttttaaaaa gatggacttc
301 agcagaaatc tttatgatat tggggaacaa ctggacagtg aagatctggc ctccctcaag
361 ttcctgagcc tggactacat tccgcaaagg aagcaagaac ccatcaaggat gccttgatg
421 ttattccaga gactccagga aaagagaatg ttggaggaaa gcaatctgtc cttcctgaag
481 gagctgctct tccgaattaa tagactggat ttgctgatta cctacctaaa cactagaaag
541 gaggagatgg aaagggaact tcagacacca ggcagggctc aaatttctgc ctacagggtc
721 atagagatgg agaagagggt catcctggga gaaggaaagtt ggacatcct gaaaagagtc
781t gtgcccaaa tcaacaagag cctgctgaag ataatcaacg actatgaaga attcagcaaa
601 atgctctatc agatttcaga agaagtgagc agatcagaat tgaggtcttt taagtttctt
661 ttgcaagagg aaatctccaa atgcaaactg gatgatgaca tgaacctgct ggatattttc
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Figure 2: The cDNA and protein sequences of the novel isoform of caspase-8 (caspase-8s). (a) The sequence from start codon ATG to stop
codon TAG of caspase-8s comparing with caspase-8. the sequence underlined is the deletion region. (b) The protein sequence of caspase-
8 and caspase-8s. (c) Scheme illustrates that the deletion may result in the termination of the transcript in advance with the predicted
generation of 108aa protein.
proteins[25–29].Caspase-8proteinhastwoDEDs,whichare
essential for the binding between the caspase-8 prodomain
and FADD by yeast two-hybrid experiments [4, 5]. Previous
studies using deletion and chimeric mutants of caspase-8
DEDs demonstrated that the two domains are necessary for
caspase-8 to function normally, and when one domain was
deleted, function of the resulting mutant protein decreased
to about half that of normal caspase-8 [30]. Liu et al. [17]
reportedanovelcaspase-8mutantwithanaturallyoccurring
deletion of leucine 62 in the ﬁrst DED, which failed to inter-
act with FADD and lost proapoptotic activity. Carrington
et al. [31] identiﬁed a procaspase-speciﬁc binding surface
on the DED of FADD, suggesting a preferential interaction
with one, but not both, of the DEDs of procaspase-8 in a
perpendicular arrangement. All these showed that there is a
controversy about the functions of the two DEDs. The novel
caspase-8s isoform we obtained only carries the ﬁrst DED
and a small part of the second DED, but it still can interact6 Journal of Biomedicine and Biotechnology
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Figure 3: SDS–PAGE analysis of caspase-8s protein expression in human AL bone marrow cells: lane 1–4: acute leukemia patient samples;
50μg of total protein from lysates of human AL bone marrow cells were subjected to 10% SDS-PAGE and immunoblotted with the rabbit
antiprocaspase-8 corresponding to the N-terminal of human caspase-8 prodomain (C7849, Sigma). In addition to the two expected bands
(55kd or 53kd) representing wild type caspase-8a/b, a small band (13kd) representing caspase-8s was identiﬁed in lane 1.
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Figure 4: Interaction of the caspase-8s-2DED and FADD. (a) Western blot analysis of the expression of cellular extracts from 293T cells
transfectedwithexpressionconstructsencodingcaspase-8-2DED(24kd,lane1),caspase-8s-2DED(13kd,lane2),andFADD(28kd,lane3)
by antiprocaspase-8 and anti-FADD antibodies, respectively. (b) 293T cells were cotransfected with expression constructs for human FADD
and caspase-8-2DED, lysed and immunoprecipitated (IP) with anti-FADD polyclonal antibody and immunoblotted with antiprocaspase-8.
The upper band in IP lane is rabbit IG heavy chain. 50μg total cell lysate was loaded as control (WB). (c) 293T cells were cotransfected with
expression constructs for human FADD and caspase-8s-2DED, and the co-immunoprecipitation assay was done as (b). (d) 293T cells were
cotransfectedwithexpressionconstructsforhumanFADDandcaspase-8s-2DED,lysedandimmunoprecipitated(IP)withantiprocaspase-8
and immunoblotted with anti-FADD polyclonal antibody. NS indicates the unspeciﬁed bands; 50μg total cell lysate was loaded as control
(WB).
with FADD, indicating that the ﬁrst but not the second DED
represents a crucial element in interaction between caspase-
8 and FADD, and that the second DED is not a necessary
domain for caspase-8 to bind to FADD.
3.3. Overexpression of Caspase-8s Increased Sensitivity to
Apoptosis in Jurkat Cells. The ability of caspase-8s to
integrate with FADD in vivo suggests that it might be
involved in apoptosis pathway. To test this possibility, we
stably transfected Jurkat cells with a lentivector expression
vector construct encoding caspase-8s. The Jurkat cell line
was chosen by two reasons: ﬁrst, caspase-8s expression was
detected to be lower than caspase-8 expression in this cell
line; second, the cell line was sensitive to apoptosis stimuli
such as anti-Fas antibody. Individual clones with green
ﬂuorescentprotein(GFP)expressionwereisolatedbylimited
dilution and successful expression of caspase-8s constructs
was conﬁrmed by Western blot analysis (Figure 5). Western
blot revealed that wild type Jurkat cells and pCDH-empty
vector-Jurkat cell clone JP4 did not express caspase-8s pro-
teinandthatthepCDH-caspase-8s-JurkatcellclonesJS2and
JS3 expressed caspase-8s protein, and that they all expressedJournal of Biomedicine and Biotechnology 7
JS2 JS3 JP4 Jurkat
55kd
13kd
Caspase-8a
Caspase-8s
Figure 5: Western bolt identiﬁed the protein expression of caspase-
8s in caspase-8s-transfected cell clones: 50μg of total protein from
lysates of empty vector (JP4 clone) or caspase-8s-transfected (JS2
clone, JS3 clone) Jurkat cells and wild-type Jurkat cells were
s u b j e c t e dt o1 0 %S D S - P A G Ea n di m m u n o b l o t t e dw i t ht h er a b b i t
antiprocaspase-8 (C7849, Sigma). A 13kd caspase-8s protein was
identiﬁed in JS2 and JS3. The 55kd bands were endogenous
caspase-8 protein.
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Figure 6: Caspase-8s promote cell apoptosis induced by Fas-agonistic
antibody CH11: empty vector (JP4), caspase-8s-transfected (JS2,
JS3) Jurkat cells and wild-type Jurkat cells were untreated or treated
with 50ng/mL and 75ng/mL of CH11 for 24h. After stimulation,
the cells were collected and resuspended in standard buﬀer solution
to a concentration of 106 cells/mL. Cells were incubated with in
Annexin V-PE and 7-amino-actinomycin (7-AAD) for 15min and
analyzed on the FACScan. Early apoptotic cells were deﬁned as
those cells with Annexin V-PE staining in the absence of 7-AAD
staining. Vector control transfected, caspase-8s-transfected, and
wild type cells were analyzed in parallel. Apoptosis assays were run
in triplicate revealing similar results (mean±SD).
M Jurkat JP4 JS2
Figure 7: DNA fragmentation after exposure to Fas-agonistic anti-
body CH11: empty vector (JP4) or caspase-8s-transfected (JS2)
Jurkat cells and wild-type Jurkat cells were treated with 75ng/mL
of CH11 for 24h and genomic DNA extracted as described in
“Materials and Methods” before electrophoresis in a 2.0% agarose
gel.
endogenous caspase-8. To evaluate the eﬀect of caspase-8s
expression on FAS-induced apoptosis, the annexin V–PE/7-
amino-actinomycin D (7-AAD) apoptosis detection kit was
used; JS2 and JS3 cells displayed higher apoptosis rates when
compared to wild type Jurkat and JP4 cells treated with serial
dilutionsofCH11(Figure 6).DNAfragmentformationassay
which is the characteristic for apoptosis also indicated DNA
degradation of JS2 cells treated with CH11 comparing to
wild type Jurkat cell, and JP4 cells (Figure 7). In addition,
the methyl thiazoleterazolium (MTT) assays showed that
the mean growth inhibitory rate of CH11 for JS2 cells was
higher than that of wild type Jurkat cells and JP4 cells. There
was no signiﬁcant diﬀerence between wild type Jurkat cells
and JP4 cells (Figure 8). These data suggested that caspase-
8s itself might not exhibit proapoptotic activity; however,
overexpressed caspase-8s promoted cell apoptosis and DNA
fragmentation formation induced by death receptor agonists
(anti-Fas antibodies).
In fact, some other DED-containing proteins are found
to regulate apoptotic signal pathways. c-FLIP and PEA-
15 (phosphoprotein enriched in astrocytes 15-Kda) inhibit
apoptosis by blocking recruitment of the caspases into
aggregates [25, 32]. FADD, caspase-8d, and artiﬁcially
constructed caspase-8 prodomains induce apoptosis when
highly overexpressed [3]. The function of DED proteins in
apoptosis has been extensively reviewed elsewhere [33]. In
our study, caspase-8s might be involved in the progression of
apoptosis pathway, but the deﬁnite mechanism still needs to
be conﬁrmed. In Fas signaling apoptosis, two pathways are
involved, in which the activation of caspase-8 is diﬀerent. In
type I pathway, induction of apoptosis was accompanied by
activation of large amounts of caspase-8 by DISC, whereas
in type II pathway, DISC formation was strongly reduced
andactivationofcaspase-8andcaspase-3occurredfollowing8 Journal of Biomedicine and Biotechnology
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Figure 8:MTTassaysEmptyvector(JP4)orcaspase-8s–transfected
(JS2) Jurkat cells and wild-type Jurkat cells were untreated or
treated with 25ng/mL, 50ng/mL, and 75ng/mL of CH11 for 24h.
The wells containing nonexposed cells were deﬁned as having 100%
viability. The data are from 3 independent MTT experiments and
represent as mean ± SD.
the loss of mitochondrial transmembrane potential; how-
e v e r ,i nt y p eI Ib u tn o tt y p eIp a t h w a y ,o v e r e x p r e s s i o no f
Bcl-2 or Bcl-xL blocked caspase-8 and caspase-3 activation
as well as apoptosis [34, 35]. Gonzalvez et al. showed that
cardiolipin is required for apoptosis in the type II mito-
chondriadependentresponsetoFasstimulation.Cardiolipin
provides an anchor and activating platform for caspase-
8 translocation to, and embedding in, the mitochondrial
membrane, where it oligomerizes and is further activated
[36]; whether caspase-8s binds to mitochondria and induces
apoptosis. Since Jurkat cells are of type II cells, to further
exploretheeﬀectofcaspase-8sexpressiononapoptosispath-
way, DiOC6/PI test was used to monitor the mitochondrial
membrane potential. CH11(50ng/mL) induced a decrease
of DiOC6 staining about 79% in caspase-8s-transfected
Jurkat cells JS2, but the mitochondrial membrane potentials
of empty vector-transfected Jurkat cells JP4 and wild-type
Jurkat cells were not signiﬁcantly inﬂuenced by CH11
(Figure 9). This indicates that caspase-8s overexpression may
induce apoptosis in mitochondria dependent way.
In the study, to exclude the eﬀect of lentiviral transduc-
tion of Jurkat cells on the expression of FAS antigen, RT-PCR
and ﬂow cytometry were performed to detect the expression
of Fas mRNA and protein in empty vector or caspase-8s-
transfected Jurkat cells and wild-type Jurkat cells. The results
indicated that there was no statistically signiﬁcant diﬀerence
in Fas expression between wild Jurkat cells and lentiviral
transfected Jurkat cells (Figures 10 and 11). Balcaitis et al.
[37] had examined the eﬀect of lentiviral transduction of
microglial cells on the expression of cell surface markers by
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Figure 9: Mitochondrial membrane depolarization was assessed by
the loss of DiOC6 staining of the mitochondria: ﬂow cytometric
analysis of the eﬀect of anti-Fas mAb (CH11) treatment on
mitochondrial transmembrane potential of empty vector (JP4) or
caspase-8s–transfected Jurkat cells (JS2) and wild-type Jurkat cells.
Cells untreated and treated with 50ng/mL CH11 for 24h were
double stained with DiOC6 and PI. Data shown are representative
of three independent experiments.
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Ratio 0.951 0.932 0.964
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225bp GAPDH
Figure 10: Expression of Fas mRNA in empty vector or caspase-
8s-transfected Jurkat cells and wild-type Jurkat cells was detected
by semiquantitative RT-PCR: the PCR products were resolved on
1.5% agarose gel and visualized by ethidium bromide staining. The
eﬃcacy of RT-PCR was veriﬁed by detection of the human GAPDH
mRNA. R = densitometrical units of Fas/densitometrical units of
GAPDH.
ﬂow cytometry including FAS antigen; no diﬀerence of Fas
antigen expression was observed.
4. Conclusion
In conclusion, a novel isoform of caspase-8, named caspase-
8s, was identiﬁed in human leukemia patients and healthy
individuals. The transcript encodes the ﬁrst and part of the
second stretches of DED but lacks the proteolytic domain.
Caspase-8s promoted the apoptosis induced by anti-Fas
antibodies. Caspase-8s may participate in the regulation ofJournal of Biomedicine and Biotechnology 9
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Figure 11: Expression of Fas Antigen in empty vector or caspase-8s–transfected Jurkat cells and wild-type Jurkat cells was analyzed by ﬂow
cytometry. (a) Analysed Jurkat cells were gated according to their size (FSC) and granularity (SSC). (b) Jurkat cell incubated with PE
conjugatedmouseIgG1asisotypenegativecontrol.(c)JP4(GFPpositivecells)incubatedwithPEconjugatedmouseIgG1asisotypenegative
control. (d–f) Expression of Fas antigen in wild-type Jurkat cells, empty vector and, caspase-8s-transfected Jurkat cells. Numbers indicate
the percentage of cells in the quadrant. Data shown are representative of three independent experiments.
caspasecascade.Inaddition,wealsofoundthattheﬁrstDED
was an important structure mediating combination between
caspase-8 and FADD. In AL patients, imbalanced expression
of caspase-8s is being studied in our laboratory. Further
research is needed to elucidate the function of caspase-8s in
apoptosis.
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